VTP-1000 / Barinthus Bio - LARVOL DELTA

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update (GlobeNewswire) - "Announcement of single ascending dose data from AVALON, the first-in-human Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-1000 in adults with celiac disease expected in the middle of 2025. Initiation of multiple ascending dose portion of the Phase 1 clinical trial expected in the third quarter of 2025."

P1 data • Trial status • Celiac Disease

VTP-1000 in Adults With Celiac Disease (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Barinthus Biotherapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Celiac Disease • Immunology

VTP-1000 in Adults With Celiac Disease (clinicaltrials.gov) - P1 | N=45 | Not yet recruiting | Sponsor: Barinthus Biotherapeutics | Trial completion date: Aug 2025 ➔ Jun 2026 | Initiation date: Apr 2024 ➔ Aug 2024 | Trial primary completion date: Aug 2025 ➔ Jun 2026

Trial completion date • Trial initiation date • Trial primary completion date • Celiac Disease • Immunology

VTP-1000 in Adults With Celiac Disease (clinicaltrials.gov) - P1 | N=45 | Not yet recruiting | Sponsor: Barinthus Biotherapeutics

New P1 trial • Celiac Disease • Immunology

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments (GlobeNewswire) - "In 2023, the Company expects to: Announce the dosing of the first patient in PCA001, a Phase 1/2 clinical trial of VTP-850 designed to evaluate the safety, PSA response, and immunogenicity of the VTP-850 heterologous immunotherapeutic as monotherapy in men with rising PSA after definitive local therapy for their disease (i.e., biochemical recurrence)....Submit IND applications for its two lead SNAPvax candidates, VTP-1000 for the treatment of celiac disease and VTP-1100 for the treatment of HPV-associated cancers."

IND • P1/2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor